These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8962246

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3.
    Bemelman FJ, Buysmann S, Wilmink JM, Surachno S, Hack CE, Schellekens PT, ten Berge RJ.
    Transplant Proc; 1994 Dec; 26(6):3096-7. PubMed ID: 7527944
    [No Abstract] [Full Text] [Related]

  • 3. Activation of coagulation and fibrinolysis during treatment with OKT3.
    ten Berge RJ, Raasveld MH, van Diepen FN, Hack CE.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):566-7. PubMed ID: 8438416
    [No Abstract] [Full Text] [Related]

  • 4. Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects.
    Kandaswamy R, Kamps M, Matas AJ.
    Transplantation; 1999 Sep 15; 68(5):709-10. PubMed ID: 10507495
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
    Piatosa B, Grenda R, Prokurat S.
    Transplant Proc; 1993 Aug 15; 25(4):2574. PubMed ID: 8356675
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK, Provenzano R, Tayeb J, Satmary N, Jones B.
    Clin Transplant; 1998 Aug 15; 12(4):343-7. PubMed ID: 9686329
    [Abstract] [Full Text] [Related]

  • 11. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.
    Kupin W, Venkat KK, Ikemiyashiro D, Ocdol H, Mozes M, Anaise D, Johnson C.
    Transplant Proc; 1993 Feb 15; 25(1 Pt 1):572-4. PubMed ID: 8438419
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-dose OKT3 for cadaveric renal transplantation.
    Schweizer RT, Roper L, Hull D, Bartus SA.
    Transplant Proc; 1992 Dec 15; 24(6):2592-3. PubMed ID: 1465875
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reduction of the initial febrile response to OKT3 with indomethacin.
    First MR, Schroeder TJ, Hariharan S, Weiskittel P.
    Transplant Proc; 1993 Apr 15; 25(2 Suppl 1):52-4. PubMed ID: 8465426
    [No Abstract] [Full Text] [Related]

  • 17. A drug of the past, a lesson for the future.
    Vincenti F.
    Pediatr Transplant; 2005 Jun 15; 9(3):267-8. PubMed ID: 15910379
    [No Abstract] [Full Text] [Related]

  • 18. Evidence for granulocyte activation by OKT3.
    Schmaldienst S, Böhmig G, Pohanka E, Kovarik J, Zlabinger GJ.
    Transplant Proc; 1992 Dec 15; 24(6):2600-1. PubMed ID: 1465878
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.